导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -21.08% | 4443/4773 |
| 近一周 | -4.29% | 5075/5465 |
| 近一月 | -3.56% | 2634/5421 |
| 近一季 | -6.37% | 2383/5231 |
| 近半年 | -19.99% | 4386/4920 |
| 近一年 | -26.76% | 4123/4394 |
| 近两年 | 3.74% | 2841/2954 |
| 近三年 | -33.44% | 2229/2253 |
| 成立以来 | -47.48% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-9.55% 4384/4961 |
-12.42% 4402/5312 |
- - |
- - |
| 2025 | 2.44% 3188/4813 |
-5.59% 3301/3635 |
-1.48% 3173/4076 |
21.12% 1847/4524 |
-9.07% 4003/4813 |
| 2024 | -0.35% 2108/3463 |
-9.01% 2260/2808 |
-11.93% 2573/3014 |
36.00% 76/3129 |
-8.57% 2866/3463 |
| 2023 | -26.81% 1994/2656 |
-5.46% 2155/2280 |
-9.73% 2066/2385 |
0.62% 359/2515 |
-14.76% 2483/2655 |
| 2022 | -10.87% 221/2207 |
8.46% 19/1919 |
-10.13% 1907/2016 |
-7.77% 142/2113 |
-0.86% 1652/2208 |
| 2021 | -6.05% 994/1822 |
-2.15% 589/1255 |
-5.06% 1271/1330 |
0.79% 462/1466 |
0.34% 1132/1822 |
| 2020 | -6.54% 976/1250 |
-13.42% 927/1028 |
7.93% 834/1067 |
7.37% 788/1164 |
-6.84% 1148/1184 |
| 2019 | 29.43% 504/1092 |
33.79% 129/754 |
-8.95% 622/804 |
-3.93% 751/850 |
10.59% 116/918 |
| 2018 | -26.98% 410/834 |
- - |
- - |
- - |
-5.72% 39/691 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 南方中证房地产ETF VS. 长安沪深300非周期A(740101) |